What's new

Opinion/decision on a Paediatric investigation plan (PIP): Zolgensma, Onasemnogene abeparvovec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0149/2024

Opinion/decision on a Paediatric investigation plan (PIP): Zolgensma, Onasemnogene abeparvovec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0149/2024

Jun 13, 2025 - 08:25
 0
Opinion/decision on a Paediatric investigation plan (PIP): Zolgensma, Onasemnogene abeparvovec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0149/2024
Opinion/decision on a Paediatric investigation plan (PIP): Zolgensma, Onasemnogene abeparvovec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0149/2024
Read More

Tags:

Previous Article

L’Oréal Is Launching a Global Campaign for World Refill Day

Next Article

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab,...

Related Posts

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 13:50 (CEST)

EMA roundtable with stakeholders on the 20th anniversar...

Jun 4, 2025  0

Medicines for human use under evaluation

Medicines for human use under evaluation

May 14, 2025  0

EMEA-002746-PIP01-20-M03

EMEA-002746-PIP01-20-M03

Jun 6, 2025  0